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Abstract
CASTOR showed the significant clinical benefit of daratumumab plus bortezomib and dexamethasone for
patients with previously treated multiple myeloma. Withw3 years median follow-up, this regimen continues to
demonstrate significantly improved progression-free survival with higher minimal residual diseaseenegativity
rates and consistent safety, with the greatest benefit observed when used earlier in the treatment of relapsed/
refractory multiple myeloma.
Background: In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and
dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median
follow-up are discussed.Patients and Methods: Eligible patients had received 1 line of treatment andwere administered
bortezomib (1.3 mg/m2) and dexamethasone (20 mg) for 8 cycles with or without daratumumab (16 mg/kg) until disease
progression.Results: Of 498patients in the intent-to-treat (ITT) population (D-Vd, n¼ 251; Vd, n¼ 247), 47%had1prior line
of treatment (1PL;D-Vd, n¼ 122; Vd, n¼ 113).Medianprogression-free survival (PFS)was significantly prolongedwithD-Vd
versus Vd in the ITT population (16.7 vs. 7.1 months; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.25-0.40;
P< .0001) and the 1PL subgroup (27.0 vs. 7.9 months; HR, 0.22; 95%CI, 0.15-0.32; P< .0001). In lenalidomide-refractory
patients, themedianPFSwas7.8versus4.9months (HR,0.44;95%CI, 0.28-0.68;P¼ .0002) forD-Vd (n¼60) versusVd (n¼
81).Minimal residualdisease (MRD)enegativity rates (105)weregreaterwithD-VdversusVd (ITT:14%vs.2%;1PL:20%vs.
3%;bothP< .0001).PFS2wassignificantlyprolongedwithD-VdversusVd (ITT:HR,0.48; 95%CI, 0.38-0.61; 1PL:HR,0.35;
95% CI, 0.24-0.51; P < .0001). No new safety concerns were observed. Conclusion: After 3 years, D-Vd maintained
significant benefits in patients with relapsed or refractory multiple myeloma with a consistent safety profile. D-Vd provided
the greatest benefit at first relapse and increased MRD-negativity rates.
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Daratumumab/Bortezomib/Dexamethasone in MyelomaIntroduction bortezomib (yes or no). All patients received eight 21-day cycles of
2In recent years, considerable progress has been made in the
treatment of multiple myeloma (MM) owing to the availability of
novel agents for use in combination with standard-of-care treatment
regimens.1 However, responses to treatment are decreased in both
duration and depth at each subsequent line of therapy, illustrating
the need to incorporate the most effective therapies earlier in the
treatment sequence to derive the greatest benefit from a given
regimen.2 The use of lenalidomide, an immunomodulatory agent
(IMiD), is increasingly prevalent as initial treatment for newly
diagnosed multiple myeloma (NDMM).3 Many frontline treatment
regimens are given until disease progression, thus limiting the value
of retaining lenalidomide for the next line of treatment.3 Protea-
some inhibitor (PI)ebased regimens are widely used for the treat-
ment of MM but, in patients with relapsed or refractory multiple
myeloma (RRMM), deep and sustained clinical responses are un-
common.4-7 The addition of novel agents to PI-based therapy re-
mains an active area of interest to address unmet needs for patients
with RRMM.3,5,8-10
Daratumumab is a human, CD38-targeted, immunoglobulin (Ig)
Gk monoclonal antibody with a direct on-tumor and immuno-
modulatory mechanism of action.11-16 In phase III studies in pa-
tients with NDMM and RRMM, daratumumab-based regimens
reduced disease progression or death risk by  44%, doubled
complete response (CR) rates, and tripled minimal residual disease
(MRD)enegativity rates.9,17-19 Based on these results, dar-
atumumab has been approved in many countries both as a mono-
therapy for heavily pre-treated patients with RRMM,20 and in
combination with standard-of-care regimens for patients with
RRMM21 and patients with NDMM.22,23
The phase III CASTOR study enrolled patients with RRMM
who had received at least 1 prior line of therapy.24 In the most
recent analysis of the study, the addition of daratumumab to the
PI bortezomib and dexamethasone (D-Vd) significantly prolonged
progression-free survival (PFS) and induced higher rates of deeper
responses than bortezomib and dexamethasone (Vd) alone in
patients with RRMM at a median follow-up of 19.4 months
(median PFS, 16.7 vs. 7.1 months; hazard ratio [HR], 0.31;
95% confidence interval [CI], 0.24-0.39; P < .0001).9 The PFS
benefit of D-Vd was especially pronounced in a subgroup of pa-
tients who had received only 1 prior line of therapy (median PFS
not reached for D-Vd compared with 7.9 months for Vd; HR,
0.19; 95% CI, 0.12-0.29; P < .0001).9 Here, we provide updated
efficacy and safety data for D-Vd versus Vd in CASTOR after a
median follow-up of 40.0 months (nearly 3 years after the primary
analysis).Patients and Methods
Study Design and Treatment
The study design and patient population of CASTOR have been
described previously.9,24 Briefly, this phase III, multicenter, ran-
domized, open-label, active-controlled trial enrolled patients with
RRMM who had received at least 1 prior line of therapy. Patients
were randomized 1:1 to receive D-Vd or Vd; randomization was
stratified by International Staging System at baseline (I, II, or III),
prior lines of therapy (1, 2, or > 3), and prior exposure toClinical Lymphoma, Myeloma & Leukemia August 20201.3 mg/m subcutaneous bortezomib (days 1, 4, 8, and 11) and
20 mg oral dexamethasone (days 1, 2, 4, 5, 8, 9, 11, and 12).
Patients in the D-Vd arm received 16 mg/kg intravenous dar-
atumumab once weekly for cycles 1 through 3 and on day 1 of
cycles 4 through 8. In the maintenance phase of the study (cycles
9þ), patients in the D-Vd arm continued to receive daratumumab
monotherapy once every 4 weeks until disease progression. After
protocol amendment, patients receiving Vd were offered dar-
atumumab monotherapy after disease progression.
Patients
Patients were eligible if they had documented MM, had received
at least 1 prior line of therapy (with at least a partial response [PR]),
and had disease progression classified per International Myeloma
Working Group criteria.25 Patients were not eligible if they had
disease refractory to bortezomib or another PI (prior bortezomib
exposure was permitted). Cytogenetic risk was evaluated using local
fluorescence in situ hybridization or karyotyping, assessed locally.
High-risk patients had t(4;14), t(14;16), or del17p cytogenetic
abnormalities.
Study Endpoints and Analyses
Endpoints for this study included PFS (primary), time to disease
progression, overall response rate (ORR), MRD negativity, and
safety (secondary). Exploratory endpoints included subgroup anal-
ysis by number of lines and type of prior therapy, as described
previously.9 Efficacy analyses were based on the intent-to-treat
(ITT) population unless otherwise specified. The response-
evaluable subset included patients with measurable disease at
screening or baseline who received  1 dose of study treatment and
had  1 post-baseline disease assessment. The safety analysis set
included all patients who received  1 dose of study treatment. PFS
on the subsequent line of therapy (PFS2) was defined as the time
from randomization to progressive disease after the next line of
subsequent therapy or death.
The entire ITT population was evaluated to allow for a stringent
and unbiased evaluation of MRD status. MRD was assessed at the
time of suspected CR and at 6 and 12 months following the first
treatment dose; an additional MRD evaluation was required every
12 months after CR. MRD was assessed via next-generation
sequencing on bone marrow aspirate samples that were ficolled
and evaluated by the United States Food and Drug
Administrationeapproved clonoSEQ assay v2.0 (Adaptive Bio-
technologies, Seattle, WA). Patients were considered to be MRD-
positive if they had an MRD-positive test result or had no MRD
assessment. The rate of MRD negativity was defined as the pro-
portion of patients who achieved MRD-negative status (assessed at a
sensitivity threshold of 105 [1 cancer cell per 100,000 nucleated
cells]) at any time point following the first treatment dose, and
compared using the Fisher exact test.
Study Oversight
The study was registered at ClinicalTrials.gov (identification
number: NCT02136134) and was sponsored by Janssen Research
& Development, LLC. All clinical study sites’ institutional review
boards or ethics committees approved this study, with all patients
Maria-Victoria Mateos et alproviding written informed consent. The study design and analyses
were devised by the investigators and sponsor. The investigators and
their research teams collected the study data. Janssen conducted the
final data analysis and verified the accuracy of the data. The in-
vestigators were not restricted by confidentiality agreements and had
full accessibility to all the data. Writing assistance was funded by
Janssen Global Services, LLC.
Results
Patients
At the time of clinical cutoff for the presented analysis (October 2,
2018), 498 patients had received treatment. The demographics and
baseline characteristics were well-balanced between treatment arms
and have been described previously.9,24 Briefly, the median age of
patients was 64 years (range, 30-88 years), and patients had received a
median of 2 prior lines of therapy (range, 1-9) (Table 1). The most
frequent prior therapies were bortezomib (66%) and thalidomide
(49%), and 48% of patients had received both a PI and an IMiD;
42% of patients had received prior lenalidomide. Lenalidomide-
refractory patients had received a median of 2 prior lines of therapy
(range, 1-10). A total of 122 (49%) patients in the D-Vd arm and
113 (46%) patients in the Vd arm had received a single line of
treatment, most frequently including an alkylating agent (89%),
IMiD (65%), or a PI (53%) (Table 1). Of these 235 patients with 1Table 1 Baseline Demographics and Clinical Characteristics
Characteristic
ITT Population
D-Vd (n [ 251) Vd (n [
Age, y
Median (range) 64 (30-88) 64 (33
75 23 (9) 35 (14
ISS staging, n (%)a
I 98 (39) 96 (39
II 94 (38) 100 (41
III 59 (24) 51 (21
Time from diagnosis, y
Median (range) 3.87 (0.7-20.7) 3.72 (0.
Prior lines of therapy, n (%)
Median (range) 2 (1-9) 2 (1-
1 122 (49) 113 (46
2 70 (28) 74 (30
3 37 (15) 32 (13
>3 22 (9) 28 (11
Prior PI, n (%) 169 (67) 172 (70
Prior bortezomib 162 (65) 164 (66
Prior IMiD, n (%) 179 (71) 198 (80
Prior thalidomide 125 (50) 121 (49
Prior lenalidomide 89 (36) 120 (49
Prior PI þ IMiD, n (%) 112 (45) 129 (52
Refractory to lenalidomide, n (%) 60 (24) 81 (33
Abbreviations: D-Vd ¼ daratumumab/bortezomib/dexamethasone; IMiD ¼ immunomodulatory dru
Vd ¼ bortezomib/dexamethasone.
aISS staging was based on the combination of serum b2-microglobulin and albumin.prior line of treatment, 18% were refractory to that therapy; 10% of
these patients were refractory to lenalidomide (6 patients receiving
D-Vd and 18 patients receiving Vd). Demographics and baseline
characteristics of patients with 1 prior line of treatment were
consistent with the overall study population (Table 1).
Disposition and Drug Exposure
At the time of this analysis, all patients in both treatment arms
had completed the protocol-specified 8 cycles of treatment with
bortezomib and dexamethasone or had discontinued study treat-
ment. The median duration of treatment was 13.4 months (range,
0-46.6 months) for the 243 D-Vdetreated patients and 5.2
months (range, 0.2-8.0 months) for the 237 Vd-treated patients.
Patients had received a median of 23 daratumumab infusions
(range, 1-58). Overall, 297 (62%) patients had discontinued
treatment, the majority (213 [44%] patients) owing to progressive
disease. For the 191 D-Vd patients who received single-agent
daratumumab maintenance therapy during cycles 9þ, median
(range) duration of monotherapy treatment was 14.8 months
(range, 0.03-41.0 months), and 50 patients continue to receive
treatment. A total of 81 patients in the Vd arm subsequently
received single-agent daratumumab after disease progression; of
these, 40 patients received single-agent daratumumab as the first
subsequent line of therapy after disease progression on Vd.1 Prior Line of Therapy Subgroup
247) D-Vd (n [ 122) Vd (n [ 113)
-85) 63 (30-84) 64 (40-85)
) 8 (7) 17 (15)
) 57 (47) 51 (45)
) 42 (34) 44 (39)
) 23 (19) 18 (16)
6-18.6) 2.81 (0.7-14.9) 2.98 (0.6-18.1)
10) 1 (1-1) 1 (1-1)
) 122 (100) 113 (100)
) 0 0
) 0 0
) 0 0
) 65 (53) 59 (52)
) 62 (51) 57 (50)
) 72 (59) 81 (72)
) 58 (48) 48 (43)
) 15 (12) 33 (29)
) 29 (24) 33 (29)
) 6 (5) 18 (16)
g; ISS ¼ International Staging System; ITT ¼ intent-to-treat; PI ¼ proteasome inhibitor;
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After a median follow-up of 40.0 months, PFS was significantly
prolonged for patients receiving D-Vd versus Vd in the ITT pop-
ulation (median PFS, 16.7 months D-Vd vs. 7.1 months Vd; HR,
0.31; 95% CI, 0.25-0.40; P < .0001) (Figure 1A). This PFS benefit
was maintained across patient subgroups, including patient age and
cytogenetic risk status (Figure 2).
The 42-month PFS rates were 22% for D-Vd and 1% for Vd.
For patients with 1 to 3 prior lines of therapy, median PFS was 18.0
months with D-Vd versus 7.3 months with Vd (HR, 0.31; 95% CI,
0.25-0.40; P < .0001). The ORR was significantly improved with
D-Vd versus Vd in the ITT population (85% vs. 63%), as were
rates of very good partial response or better ( VGPR, 63% vs.
29%) and CR or better ( CR, 30% vs. 10%; all P < .0001)
(Table 2). These deep responses correlated with longer PFS, with
patients with  CR achieving a 42-month PFS rates of 53% for
D-Vd and 10% for Vd. Time to first response (PR or better) was
significantly more rapid for patients receiving D-Vd than Vd alone
(median time to first response, 0.85 months D-Vd vs. 1.61 months
Vd; HR, 1.88; 95% CI, 1.51-2.35; P < .0001).
For the subgroup of patients with 1 prior line of therapy, the
median PFS was 27.0 months with D-Vd versus 7.9 months with Vd
(HR, 0.22; 95% CI, 0.15-0.32; P < .0001) (Figure 1B). This PFS
benefit was maintained regardless of whether the prior line of therapy
included bortezomib (median 20.4 vs. 8.0 months; HR, 0.22; 95%
CI, 0.13-0.37; P< .0001) (Figure 1C) or lenalidomide (median 21.2Figure 1 PFS for the ITT Population (A); Patients Who Received 1 P
Therapy Who Were Treated With Bortezomib (C) or Lenalido
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(Figure 1D). Response rates for patients with 1 prior line of therapy
were also significantly higher for those receiving D-Vd compared
with Vd, with an ORR of 92% versus 74%, a  VGPR rate of 77%
versus 42%, and a  CR rate of 43% versus 15% (all P < .001)
(Table 2). Similar to the ITT population, time to first response was
significantly more rapid for patients receiving D-Vd than Vd alone
(median time to first response, 0.82 months D-Vd vs. 1.48 months
Vd; HR, 2.01; 95% CI, 1.47-2.74; P < .0001).
The PFS benefit derived from treatment with D-Vd compared
with Vd was also maintained for patients who were refractory to
lenalidomide in any prior line of therapy (median PFS, 7.8months vs.
4.9 months; HR, 0.44; 95% CI, 0.28-0.68; P¼ .0002) (Figure 1E).
The deep responses observed in the D-Vd arm translated to
significantly higher rates of MRD negativity at a 105 threshold,
with 35 (14%) patients receiving D-Vd achieving MRD negativity
at the time of clinical cutoff, compared with 4 (2%) patients
receiving Vd (P < .0001) (Table 2). Increased rates of MRD
negativity were also seen in the subgroup of patients who received 1
prior line of therapy, with 24 (20%) patients receiving D-Vd
attaining MRD-negative status compared with 3 (3%) patients
receiving Vd (P < .0001) (Table 2). Across treatment groups, pa-
tients achieving MRD negativity had prolonged PFS compared with
patients who did not achieve MRD negativity (Figure 3). The
median PFS was not estimable for MRD-negative patients receiving
D-Vd and 37.6 months for patients receiving Vd; for patients whorior Line of Therapy (B); PFS for Patients With 1 Prior Line of
mide (D); and Patients in the ITT Population Who Were Refractory
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Figure 2 PFS in Pre-specified Patient Subgroups
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hybridization; IgG ¼ immunoglobulin G; IMiD ¼ immunomodulatory drug; ISS ¼ International Staging System; MM ¼ multiple myeloma; PFS ¼ progression-free survival; Vd ¼ bortezomib/
dexamethasone.
aCytogenetic risk status by fluorescence in situ hybridization or karyotype testing. bHigh-risk patients had t(4;14), t(14;16), or del17p cytogenetic abnormalities by FISH or karyotyping.
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and 6.8 months, respectively. Regardless of MRD status, patients
receiving D-Vd experienced significantly prolonged PFS compared
with those receiving Vd alone (MRD-negative: HR, 0.31; 95% CI,
0.10-1.01; P ¼ .041; MRD-positive: HR, 0.40; 95% CI,
0.32-0.50; P < .0001).
Patients in the D-Vd arm had a significantly increased median
time to subsequent therapy compared with patients in the Vd arm(ITT, 25.4 vs. 9.7 months; HR, 0.27; 95% CI, 0.21-0.35;
P < .0001). A similar difference between treatment arms was
observed for patients treated with 1 prior line of therapy (33.3 vs.
11.1 months; HR, 0.22; 95% CI, 0.15-0.32; P < .0001).
PFS2 was significantly prolonged with D-Vd compared with Vd in
the ITT population (median 34.2 vs. 20.3 months; HR, 0.48;
95% CI, 0.38-0.61; P< .0001) (Figure 4A). In the ITT population,
42-month PFS2 rates were 42% and 14% for D-Vd and Vd,Clinical Lymphoma, Myeloma & Leukemia August 2020 - 513
Table 2 Response and MRD-negativity Rates in the Overall Population and in Patients With 1 Prior Line of Therapy
ITT Population 1 Prior Line of Therapy Subgroup
D-Vd Vd P Value D-Vd Vd P Value
Response, n (%)a n ¼ 240 n ¼ 234 n ¼ 119 n ¼ 109
ORR 203 (85) 148 (63) < .0001 109 (92) 81 (74) .0007
 CR 72 (30) 23 (10) < .0001 51 (43) 16 (15) < .0001
sCR 23 (10) 6 (3) 17 (14) 5 (5)
CR 49 (20) 17 (7) 34 (29) 11 (10)
 VGPR 151 (63) 68 (29) < .0001 91 (77) 46 (42) < .0001
VGPR 79 (33) 45 (19) 40 (34) 30 (28)
PR 52 (22) 80 (34) 18 (15) 35 (32)
MRD-negative (10e5)b n ¼ 251 n ¼ 247 n ¼ 122 n ¼ 113
n (%) 35 (14) 4 (2) < .000001 24 (20) 3 (3) .000025
Abbreviations: CR ¼ complete response; D-Vd ¼ daratumumab/bortezomib/dexamethasone; ITT ¼ intent-to-treat; MRD ¼ minimal residual disease; ORR ¼ overall response rate; PR ¼ partial
response; sCR ¼ stringent complete response; Vd ¼ bortezomib/dexamethasone; VGPR ¼ very good partial response.
aResponse-evaluable population.
bITT population.
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514 -respectively. Similar PFS2 benefits were observed for patients in the 1
prior line of therapy subgroup (median not reached vs. 23.3 months;
HR, 0.35; 95%CI, 0.24-0.51; P< .0001), and 42-month PFS2 rates
were 54% versus 19%, respectively (Figure 4B). PFS2 was signifi-
cantly prolonged in the subgroup of patients in the Vd group who
received daratumumab monotherapy as their next line of therapy at
disease progression (n¼ 40) compared with other patients in the Vd
group (n ¼ 207) who did not switch to daratumumab monotherapyFigure 3 PFS by MRD Status for the ITT Population
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Clinical Lymphoma, Myeloma & Leukemia August 2020or switched to daratumumab monotherapy but not as the first line of
subsequent anticancer therapy (median 31.6 vs. 17.2 months; HR,
0.43; 95% CI, 0.27-0.66; P < .0001).
Median overall survival (OS) has not been reached. At the time of
analysis, 102 deaths in the D-Vd arm and 119 deaths in the Vd arm
were observed. For patients with 1 prior line of treatment, 35 deaths
in the D-Vd arm and 51 deaths in the Vd arm have occurred.
Follow-up for OS is ongoing.48274
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Maria-Victoria Mateos et alSafety
The safety population included 243 patients who received D-Vd
and 237 patients who received Vd. With extended follow-up, no
new safety concerns were observed compared with previousanalyses9,24 (Table 3). The most common ( 10%) grade 3/4
treatment-emergent adverse events (TEAEs) in the D-Vd versus Vd
arms were thrombocytopenia (46% vs. 33%), anemia (16% vs.
16%), and pneumonia (10% vs. 10%). Rates of grade 3/4 infectionClinical Lymphoma, Myeloma & Leukemia August 2020 - 515
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516 -were higher for D-Vd versus Vd (29% vs. 19%); however, after
adjusting for exposure, grade 3/4 infection events per patient-year
were lower with D-Vd versus Vd (0.26 vs. 0.68). Rates of discon-
tinuation owing to TEAEs were similar for D-Vd versus Vd
(10% vs. 9%).
With longer follow-up, second primary malignancies (cutaneous,
invasive, and hematologic) were reported in 14 (6%) patients in the
D-Vd arm (4 new cases since the previous analysis) and 5 (2%)
patients in the Vd arm (4 new cases since the previous analysis). No
cancer type was predominant for second primary malignancies in
either treatment arm.
Discussion
With greater than 3 years of median follow-up, D-Vd maintains
significant PFS and ORR benefits compared with Vd alone in pa-
tients with RRMM. The safety profile remains consistent after
40 months of follow-up, emphasizing the tolerability and predict-
ability of daratumumab monotherapy following 8 cycles of D-Vd.
Although the PFS benefit of D-Vd over Vd was observed regardless
of the number of prior lines of therapy, the benefit was more
pronounced in patients who had received 1 prior line of treatment,
and was maintained regardless of whether the first-line regimen
included bortezomib or lenalidomide. D-Vd also improved out-
comes versus Vd alone for the increasingly clinically important
group of patients who were refractory to lenalidomide in any prior
line of treatment.3
Responses to therapy with D-Vd were deep and durable overall,
and were more pronounced for patients with 1 prior line of
treatment, with 92% of patients achieving at least a PR
(43% with  CR) and 20% achieving MRD negativity at a 10e5
sensitivity threshold. These findings in patients who relapsed after
or were refractory to their first line of treatment suggest a need toTable 3 Most Common (> 20% of Patients) and Grade 3/4 (> 5% o
TEAE, n (%)
All Grades
D-Vd (n [ 243) Vd (n
Hematologic
Thrombocytopenia 145 (60) 10
Anemia 71 (29) 7
Neutropenia 48 (20) 2
Lymphopenia 32 (13)
Non-hematologic
Peripheral sensory neuropathy 121 (50) 9
Upper respiratory tract infection 85 (35) 4
Diarrhea 86 (35) 5
Cough 71 (29) 3
Constipation 54 (22) 3
Fatigue 55 (23) 5
Back pain 53 (22) 2
Pneumonia 38 (16) 3
Hypertension 24 (10)
Abbreviations: D-Vd ¼ daratumumab/bortezomib/dexamethasone; TEAE ¼ treatment-emergent adve
Clinical Lymphoma, Myeloma & Leukemia August 2020integrate effective therapies early in the course of treatment to drive
patients toward MRD negativity, which has been shown to correlate
with favorable long-term outcomes in NDMM.26,27 In this study of
patients with RRMM, MRD negativity was also associated with
prolonged PFS irrespective of treatment, although the majority of
MRD-negative patients had received D-Vd. Achieving deep re-
sponses, such as MRD negativity, is an important treatment goal
but, as seen in this study, some patients will eventually relapse. The
durability of an MRD-negative response is an important factor in
determining long-term outcomes.25 Preliminary data from the
CASTOR study identified a cohort of patients who achieved MRD
negativity that sustained this response for over 6 months and in
some cases for more than 12 months.28 In these patients, sustained
MRD was associated with improved PFS and OS. It should be
noted, however, that this largely lenalidomide-naive patient popu-
lation does not reflect the increasingly common group of patients
who received lenalidomide in the first line of therapy observed in
clinical practice.
Following disease progression, patients who received D-Vd had a
significantly prolonged PFS2 compared with those who received
Vd, despite 81 patients in the Vd group receiving daratumumab
monotherapy after disease progression. PFS2 was significantly pro-
longed in the 40 patients in the Vd group who received dar-
atumumab monotherapy as their first subsequent therapy after
disease progression compared with those who did not switch to
daratumumab or who switched to daratumumab after additional
subsequent therapy (not as the first line of subsequent therapy),
suggesting that daratumumab monotherapy is superior to other
salvage therapies following progression on Vd. Although survival
data remain immature in this study, PFS2 is a recommended sur-
rogate endpoint for OS,29 and these PFS2 data suggest there may be
a survival benefit.f Patients) TEAEs in the Safety Population
Grade 3/4
[ 237) D-Vd (n [ 243) Vd (n [ 237)
5 (44) 112 (46) 78 (33)
5 (32) 38 (16) 38 (16)
3 (10) 33 (14) 11 (5)
9 (4) 24 (10) 6 (3)
0 (38) 11 (5) 16 (7)
3 (18) 6 (3) 1 (0.4)
3 (22) 9 (4) 3 (1)
0 (13) 0 0
8 (16) 0 2 (0.8)
8 (25) 12 (5) 8 (3)
4 (10) 6 (3) 3 (1)
1 (13) 25 (10) 24 (10)
8 (3) 16 (7) 2 (0.8)
rse event; Vd ¼ bortezomib/dexamethasone.
Maria-Victoria Mateos et alThe safety profile of D-Vd remains consistent after extended
follow-up, during which a substantial number of patients continued
to receive daratumumab monotherapy. Infection rates adjusted for
exposure reveal that daratumumab does not increase the rates of
infection. The results observed with extended follow-up suggest no
cumulative toxicity, and these findings highlight the tolerability of
daratumumab monotherapy used as maintenance treatment
following 8 cycles of D-Vd. Rates of second primary malignancies
were consistent with rates observed for patients with RRMM
overall, and no notable increases were observed since the previous
analysis of CASTOR.9 A concern of adding a new agent to doublet
regimens is that this may place an additional burden on patients.
However, in an earlier update of the CASTOR study, it was re-
ported that adding daratumumab to Vd does not worsen health-
related quality of life.9
The outcomes of patients with RRMM treated with D-Vd
compare favorably with other clinical trials in this patient popula-
tion. In a subgroup analysis of the phase III ENDEAVOR study of
carfilzomib-dexamethasone (Kd) versus Vd, patients with 1 prior
line of treatment achieved a median PFS of 22.2 months versus
10.1 months, respectively (HR, 0.45; 95% CI, 0.33-0.61;
P < .0001) after approximately 11 months of follow-up.30 A ran-
domized phase II study of SLAMF7-targeted monoclonal antibody
elotuzumab in combination with Vd (Elo-Vd) versus Vd alone
demonstrated a median PFS of 9.7 months with Elo-Vd versus 6.9
months with Vd after a median follow-up of 15.9 and 11.7 months,
respectively.7 In the phase III OPTIMISMM trial of pomalidomide
plus Vd versus Vd alone in lenalidomide-exposed patients, the
median PFS was 11.2 months versus 7.1 months after a median
follow-up of 16 months (HR, 0.61; 95% CI, 0.49-0.77; P < .0001)
in the ITT population. For patients with 1 prior line of therapy, the
median PFS was 20.7 months versus 11.6 months (HR, 0.54; 95%
CI, 0.36-0.82; P ¼ .0027).10 As depth and duration of response to
treatment decrease with each subsequent line of therapy for patients
with MM, and as many patients do not proceed to further treat-
ment, there remains an unmet need for effective therapies that can
be administered early in the treatment course.31 Another
daratumumab-containing regimen has been shown to provide
clinical benefit when used earlier in the treatment of RRMM: after
25.4 months of median follow-up in the phase III POLLUX study,
the median PFS was not reached for daratumumab plus lenalido-
mide and dexamethasone versus a median PFS of 19.6 months with
lenalidomide and dexamethasone alone in patients with 1 prior line
of treatment.18
The combination of daratumumab plus Vd also was efficacious in
patients who were refractory to lenalidomide in prior treatment lines.
Daratumumab in combination with a different PI (carfilzomib) and
dexamethasone (D-Kd) has also shown a clinical benefit in
lenalidomide-refractory patients. In the phase IbMMY1001 study, in
a subgroup of 51 lenalidomide-refractory patients with a median of 2
prior lines of treatment, the 12-month PFS rate was 69%.32 A phase
III study of D-Kd versus Kd (CANDOR; NCT03158688) is further
evaluating this combination in patients with RRMMwith 1 to 3 prior
lines of therapy. Daratumumab plus pomalidomide and dexameth-
asone (D-Pd) is also an effective regimen in RRMM and is approved
in the United States.33,34 A European Myeloma Network phase III
study (APOLLO) is evaluating D-Pd compared with Pd alone inpatients with RRMM previously treated with a PI or an IMiD
(NCT03180736). Patients with 1 prior line of treatment are required
to be refractory to lenalidomide. These studies will provide further
information on the efficacy of daratumumab-based combinations for
the treatment of patients who are refractory to lenalidomide after their
first line of therapy.Conclusion
With extended follow-up, significant improvements in PFS,
ORR, and MRD negativity were observed for patients with RRMM
treated with D-Vd versus Vd alone, and were especially pronounced
in patients with 1 prior line of therapy. No new safety concerns were
observed, supporting the tolerability and predictability of dar-
atumumab monotherapy used as maintenance treatment.
Clinical Practice Points
 New treatment options are required for patients with MM, as
depth and duration of response decrease with subsequent lines of
therapy.
 D-Vd is a widely used triplet regimen for the treatment of pa-
tients who have relapsed after 1 or more prior lines of therapy.
Approval was based on the phase III CASTOR study.
 The CASTOR study is ongoing, and, after an extended follow-
up of 40.0 months, D-Vd showed improved efficacy outcomes
(including PFS, ORR, and MRD-negativity rate) compared with
Vd alone.
 In the approved regimen, patients discontinue Vd after 8 cycles
and remain on daratumumab monotherapy. No new safety
concerns were observed for daratumumab monotherapy with
extended follow-up, and rates of discontinuation owing to
TEAEs remain low.
 Greater improvement in response was observed in patients with
1 prior line of therapy. Outcomes were also significantly
improved in patients who were refractory to lenalidomide, a
subset of patients that physicians are increasingly encountering
owing to the use of this IMiD in frontline treatment.Acknowledgments
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